Credit Suisse analsyt Vamil Divan raised Portola Pharmaceuticals' price target to $29 from $20 following the announcement late Friday the FDA accepted its New Drug Application and EMA validation of the Marketing Authorization for betrixaban for use in acute medically ill patients. The FDA also assigned priority review for the application, setting up an action date of June 24, 2017. Given the Fast Track Status betrixaban has, the general understanding the FDA must already have of the APEX study results and the support the drug seems to have both with officials at the FDA and with thought leaders in the community, Divan increased his probability of success for betrixaban to 65% from 40%. The analyst has a Neutral rating on Portola shares.